GlassScriptPhysician profile
Laura Oppenheim
NPI 1275695629
$4,855.86
in general payments reported to CMS, 2019-2025
37 companies · $1,555 in 2025
The $1,555 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $67.61 · 2021: $182 · 2022: $264 · 2023: $875 · 2024: $1,504 · 2025: $1,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,834 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,833.66 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $718.12 | 2023-2025 | |
| Amgen INC. | $679.07 | 2019-2025 | Evenity, Prolia, Otezla |
| Astellas Pharma US INC | $595.97 | 2019-2025 | Veozah |
| Novo Nordisk INC | $561.51 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $394.73 | 2019-2025 | |
| Gilead Sciences, INC. | $199.59 | 2019-2025 | Yeztugo |
| Astrazeneca Pharmaceuticals LP | $144.44 | 2020-2025 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $120.03 | 2023-2025 | |
| Glaxosmithkline, LLC. | $118.91 | 2019-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $108.38 | 2023-2025 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.45 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Eisai INC. | $89.81 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $88.17 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.25 | 2019-2025 | Xifaxan |
| Inspire Medical Systems, INC. | $78.45 | 2024-2025 | Inspire |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $66.32 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $57.55 | 2023-2025 | Eliquis, Camzyos |
| Exact Sciences Corporation | $50.43 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $48.00 | 2019-2025 | Capvaxive |
| Xeris Pharmaceuticals, INC. | $47.60 | 2024 | Gvoke Hypopen |
| Paratek Pharmaceuticals, INC. | $45.88 | 2024 | Nuzyra |
| Hologic Sales and Service, LLC | $44.57 | 2023 | Aptima |
| Biohaven Pharmaceutical Holding Company LTD. | $40.09 | 2022 | |
| Allergan, INC. | $38.72 | 2019 | |
| Janssen Pharmaceuticals, INC | $37.98 | 2019 | |
| Sanofi-Aventis U.S. LLC | $35.93 | 2023-2025 | |
| Exeltis, USA INC. | $35.08 | 2023 | Slynd |
| Inari Medical, INC. | $31.97 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Insulet Corporation | $29.82 | 2025 | Omnipod |
| Dexcom, INC. | $26.80 | 2023 | Dexcom G6 Transmitter |
| Viiv Healthcare Company | $26.63 | 2024 | Apretude |
| Boston Scientific Corporation | $26.29 | 2024 | Bodyguardian |
| Bausch Health US, LLC | $23.17 | 2025 | Wellbutrin |
| Agios Pharmaceuticals, INC. | $21.65 | 2025 | Pyrukynd |
| Neurocrine Biosciences, INC. | $16.00 | 2023 | Ongentys, Ingrezza |
| Amarin Pharma, INC. | $14.32 | 2019 | |
| Esperion Therapeutics, INC. | $13.18 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Oppenheim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.